JP2003521914A - トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター - Google Patents

トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター

Info

Publication number
JP2003521914A
JP2003521914A JP2001557910A JP2001557910A JP2003521914A JP 2003521914 A JP2003521914 A JP 2003521914A JP 2001557910 A JP2001557910 A JP 2001557910A JP 2001557910 A JP2001557910 A JP 2001557910A JP 2003521914 A JP2003521914 A JP 2003521914A
Authority
JP
Japan
Prior art keywords
inhibitor
human
milk
mammal
human mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001557910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003521914A5 (https=
Inventor
ヨハネス ヘンリクス ノイエンス，
フェーン， ヘンリクス アントニウス ファン
フランク エール． ピーピル，
ヨリス ヤン ヒュース，
Original Assignee
ファーミング インテレクチュアル プロパティー ベー．フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーミング インテレクチュアル プロパティー ベー．フェー． filed Critical ファーミング インテレクチュアル プロパティー ベー．フェー．
Publication of JP2003521914A publication Critical patent/JP2003521914A/ja
Publication of JP2003521914A5 publication Critical patent/JP2003521914A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C2230/00—Aspects relating to animal feed or genotype
    • A23C2230/05—Milk or milk products from transgenic animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
JP2001557910A 2000-01-31 2001-01-31 トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター Withdrawn JP2003521914A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17931000P 2000-01-31 2000-01-31
US60/179,310 2000-01-31
EP00200320.0 2000-01-31
EP00200320 2000-01-31
US18758000P 2000-03-07 2000-03-07
US60/187,580 2000-03-07
EP00200810.0 2000-03-07
EP00200810 2000-03-07
PCT/NL2001/000068 WO2001057079A2 (en) 2000-01-31 2001-01-31 C1 inhibitor produced in the milk of transgenic mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011270236A Division JP2012050465A (ja) 2000-01-31 2011-12-09 トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター

Publications (2)

Publication Number Publication Date
JP2003521914A true JP2003521914A (ja) 2003-07-22
JP2003521914A5 JP2003521914A5 (https=) 2008-02-28

Family

ID=56290105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557910A Withdrawn JP2003521914A (ja) 2000-01-31 2001-01-31 トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター

Country Status (9)

Country Link
EP (1) EP1252184B1 (https=)
JP (1) JP2003521914A (https=)
AT (1) ATE382635T1 (https=)
CA (1) CA2398707C (https=)
DE (2) DE60132169T2 (https=)
DK (1) DK1252184T3 (https=)
ES (1) ES2299473T3 (https=)
PT (1) PT1252184E (https=)
WO (1) WO2001057079A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520815A (ja) * 2005-12-21 2009-05-28 ファーミング インテレクチュアル プロパティ ビー．ブイ． 虚血再灌流障害を予防するためのｃ１インヒビターの使用
JP2011526495A (ja) * 2008-06-30 2011-10-13 チョ−エー・ファーム・カンパニー・リミテッド 豚のαＳ１カゼイン遺伝子、そのプロモーター、及びその用途
JP2012050465A (ja) * 2000-01-31 2012-03-15 Pharming Intellectual Pty Bv トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター
JP2016511394A (ja) * 2013-01-20 2016-04-14 ダイアックス コーポレーション ｐＫａｌ関連疾病の評価、アッセイおよび治療
JP2021515757A (ja) * 2018-02-28 2021-06-24 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． 子癇前症の治療及び予防
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
CA2502539A1 (en) * 2002-10-17 2004-04-29 Pharming Intellectual Property B.V. Protein modification
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
EP1626736B1 (en) 2003-05-16 2020-09-16 Pharming Intellectual Property B.V. C1 inhibitor with short half-life for transient treatment
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
JP2013505232A (ja) 2009-09-16 2013-02-14 スティヒティング ヘット ネーデルラント カンカー インスティテュート 癌治療のための薬剤標的としてのＦｒａ−１標的遺伝子
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
EP2354244A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of liver-specific insulin resistance
EP2354245A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of hepatic PPAR- activity
EP2608802B1 (en) 2010-08-27 2017-02-22 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
AU2013281328B2 (en) 2012-06-27 2017-11-23 MeiraGTx Gene Regulation Limited Combination for treating an inflammatory disorder
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112015023207A8 (pt) 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CA3005906A1 (en) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504715A (ja) * 1994-07-27 1998-05-12 ファーミング ビー．ブイ． トランスジェニック哺乳動物の乳汁におけるコラーゲンの産生
WO1999051724A1 (en) * 1998-04-07 1999-10-14 Pharming Intellectual Property B.V. PURIFICATION OF HUMAN ACID α-GLUCOSIDASE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
EP0497833A1 (en) * 1989-10-27 1992-08-12 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504715A (ja) * 1994-07-27 1998-05-12 ファーミング ビー．ブイ． トランスジェニック哺乳動物の乳汁におけるコラーゲンの産生
WO1999051724A1 (en) * 1998-04-07 1999-10-14 Pharming Intellectual Property B.V. PURIFICATION OF HUMAN ACID α-GLUCOSIDASE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6009021425; Ｊ．　Ｍａｍｍａｒｙ　Ｇｌａｎｄ　Ｂｉｏｌ．　Ｎｅｏｐｌａｓｉａ ３（３）（１９９８）, ｐ．３３７-３５０ *
JPN6010067861; Ｌａｂ．　Ｉｎｖｅｓｔ． ６５（４）, ｐ．３８１-３８８ *
JPN6010067863; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ． ２５３（２４）（１９８８）, ｐ．１１７７６-１１７７９ *
JPN6012012290; 'Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｉｎｖｅｓｔｉｇａｔｉｏｎ' １９８９，　Ｖｏｌ．８４，　ｐ．４４３-４５０

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012050465A (ja) * 2000-01-31 2012-03-15 Pharming Intellectual Pty Bv トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター
JP2009520815A (ja) * 2005-12-21 2009-05-28 ファーミング インテレクチュアル プロパティ ビー．ブイ． 虚血再灌流障害を予防するためのｃ１インヒビターの使用
JP2011526495A (ja) * 2008-06-30 2011-10-13 チョ−エー・ファーム・カンパニー・リミテッド 豚のαＳ１カゼイン遺伝子、そのプロモーター、及びその用途
US9738694B2 (en) 2008-06-30 2017-08-22 Cho-A Pharm. Co., Ltd. Gene of porcine alpha-s1 casein, a promoter of the same and use thereof
JP2016511394A (ja) * 2013-01-20 2016-04-14 ダイアックス コーポレーション ｐＫａｌ関連疾病の評価、アッセイおよび治療
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
US11892450B2 (en) 2013-01-20 2024-02-06 Takeda Pharmaceutical Company Limited Evaluation, assays and treatment of pKal-mediated disorders
JP2021515757A (ja) * 2018-02-28 2021-06-24 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． 子癇前症の治療及び予防
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)

Also Published As

Publication number Publication date
CA2398707A1 (en) 2001-08-09
DE122011000002I1 (de) 2011-05-05
EP1252184A2 (en) 2002-10-30
CA2398707C (en) 2010-10-26
WO2001057079A3 (en) 2002-08-15
DE60132169D1 (de) 2008-02-14
DE60132169T2 (de) 2008-12-11
ATE382635T1 (de) 2008-01-15
DK1252184T3 (da) 2008-02-04
EP1252184B1 (en) 2008-01-02
ES2299473T3 (es) 2008-06-01
PT1252184E (pt) 2008-04-15
WO2001057079A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
JP2003521914A (ja) トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター
JP2014121337A (ja) トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター
CA2093659C (en) Dna sequence encoding bovine .alpha.-lactalbumin and methods of use
JPH10506013A (ja) ヒトの凝固第ｖｉｉｉ因子及びフォンビルブラント因子を発現するトランスジェニック動物
US20090239797A1 (en) Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
US7435869B2 (en) Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin
US20130131317A1 (en) Expression of secreted human alpha-fetoprotein in transgenic animals
US6545198B1 (en) Transgenically produced prolactin
US7723563B2 (en) Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto
JPH08511688A (ja) Ｅｃ−ｓｏｄの形質転換生産
AU784724B2 (en) C1 inhibitor produced in the milk of transgenic mammals
AU2006203549B2 (en) C1 inhibitor produced in the milk of transgenic mammals
US20040117862A1 (en) Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses
US20160361394A1 (en) Treatment of hereditary angioedema with c1 inhibitor
Brem et al. Transgenesis in rabbits
AU2002254193A1 (en) Production of high levels of transgenic factor VIII with engineered stability, and its therapeutic uses
HK1121342A (en) Expression of secreted human alpha-fetoprotein in transgenic animals

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120309

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140423